Mesoblast Achieves US$30.3M Ryoncil Sales, Nears US$100M First-Year Revenue
Mesoblast reported Ryoncil net sales of US$30.3 million for the March quarter, driven by strong February–March performance offsetting January seasonality. First-year launch revenue for Ryoncil approaches US$100 million, bolstering the balance sheet and funding planned label extensions and late-stage programs.
1. Q3 Net Sales Performance
Mesoblast recorded net sales of US$30.3 million for Ryoncil during the quarter ended March 31, driven by strong performance in February and March that offset typical January seasonality.
2. First-Year Revenue Milestone
Cumulative revenue from Ryoncil’s first-year launch now approaches US$100 million, marking a significant commercial milestone for the company’s first FDA-approved mesenchymal stromal cell therapy.
3. Financial Impact and Pipeline Funding
The robust sales bolster Mesoblast’s balance sheet, providing resources to pursue label extensions—such as adult SR-aGvHD and inflammatory bowel disease—and to advance late-stage blockbuster programs across its cell therapy pipeline.
4. Upcoming R&D Day Event
Mesoblast will host its inaugural R&D Day on April 8 in New York City, where senior leadership and key opinion leaders will present growth strategies and pipeline updates via live webcast.